SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celera Genomics (CRA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rob Pierce who wrote (289)5/4/2000 2:57:00 AM
From: GlobalMarine  Read Replies (1) of 746
 
Thanks for the link. Without question, Celera is front and center. Despite concerns of some shareholders that Celera will fail because its business plan is predicated on selling subscriptions, if Venter and his crew are smart enough to sequence the human genome in record time, they're smart enough to know that with the HGP providing dirt cheap access to the genome database eventually , CRA is going to focus on identifying and patenting therapeutically important genes (I actually think it's good that they don't talk much about this, since they don't want the government to intervene out of worries Celera is going to patent all the choice genes and monopolize the field) and going after proteomics. Buy the 800 pound gorilla, one investment methodology holds. And CRA is certainly the gorilla in its field.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News